Scrip: industry news and insights
GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
26 Feb 2021
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing...
Although 10 of Japan’s largest pharma companies look set to add $11bn in revenues over the next nine years, a CAGR of only 1% reflects an expected $4.8bn in patent expiries, leaving Japanese pharma heads relying on innovation for the next phase of the region’s major wins.
For further information, context and expert analysis on Japan's pharma future follow the links below:
Pharma Report Store: Japan Pharma Outlook 2027
Webinar Discussing Japan Pharma
Innovation Critical As Japan Pharma Faces Continued Pricing Pressures
Scrip: industry news and insights
26 Feb 2021
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing...
Scrip: industry news and insights
By Anju Ghangurde 26 Feb 2021
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials...
Scrip: industry news and insights
By John Davis 26 Feb 2021
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: